• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·6857.TWO
Share

Acer Medical Inc. Stocks

NT$ 92Last Updated 28.07.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

NT$ 43.58M

NT$ 92
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Acer Medical Inc. is a company dedicated to the healthcare industry, providing advanced solutions that incorporate artificial intelligence, clinical data analysis, and specialized software. Their product lineup features VeriSee DR, an AI-powered diagnostic tool for detecting diabetic retinopathy; VeriSee AMD, an AI-enabled screening application focused on identifying age-related macular degeneration; and VeriOsteo OP, an AI-assisted screening software used to detect anomalies in bone mineral density. The company was established in 2018 and is headquartered in New Taipei City, Taiwan.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Slightly negative
3/7

The average target price of 6857.TWO is 76.6 and suggests 16.8% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

30.07.2026 02:31

The Nasdaq 100 Index closed the trading session in correction territory

30.07.2026 02:03

Microsoft Shares Rise After Earnings Report: Cloud Business Posts Best Growth Since 2022

30.07.2026 01:26

Yields on long-term U.S. Treasury bonds have reached their highest level since 2007

30.07.2026 01:20

Meta disappointed investors with its revenue forecast. Its stock fell 10%.

30.07.2026 00:34

A War Between the U.S. and Iran Could Drag On for Several Months — Bloomberg

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026